Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Moodliar R, Dodd M, Solodovnikova V, Liverko I, Rajaram S, Rassool M, McHugh T, Spigelman M, Moore DA, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL team. Nyang'wa BT, et al. Lancet Respir Med. 2024 Feb;12(2):117-128. doi: 10.1016/S2213-2600(23)00389-2. Epub 2023 Nov 16. Lancet Respir Med. 2024. PMID: 37980911 Free article. Clinical Trial.
TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
Berry C, du Cros P, Fielding K, Gajewski S, Kazounis E, McHugh TD, Merle C, Motta I, Moore DAJ, Nyang'wa BT. Berry C, et al. Among authors: nyang wa bt. Trials. 2022 Jun 13;23(1):484. doi: 10.1186/s13063-022-06331-8. Trials. 2022. PMID: 35698158 Free PMC article.
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore DAJ, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL Study Collaborators. Nyang'wa BT, et al. N Engl J Med. 2022 Dec 22;387(25):2331-2343. doi: 10.1056/NEJMoa2117166. N Engl J Med. 2022. PMID: 36546625 Clinical Trial.
Multidrug-resistant tuberculosis.
Nyang'wa BT, Berry C, Fielding K, Nunn AJ. Nyang'wa BT, et al. Lancet. 2019 Jul 27;394(10195):298-299. doi: 10.1016/S0140-6736(19)30691-9. Lancet. 2019. PMID: 31354136 No abstract available.
Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan.
du Cros P, Khamraev A, Tigay Z, Abdrasuliev T, Greig J, Cooke G, Herboczek K, Pylypenko T, Berry C, Ronnachit A, Lister D, Dietrich S, Ariti C, Safaev K, Nyang'wa BT, Parpieva N, Tillashaikhov M, Achar J. du Cros P, et al. ERJ Open Res. 2021 Feb 8;7(1):00537-2020. doi: 10.1183/23120541.00537-2020. eCollection 2021 Jan. ERJ Open Res. 2021. PMID: 33585652 Free PMC article.
Optimising recruitment to a late-phase tuberculosis clinical trial: a qualitative study exploring patient and practitioner experiences in Uzbekistan.
Wharton-Smith A, Horter S, Douch E, Gray N, James N, Nyang'wa BT, Singh J, Nusratovna PN, Tigay Z, Kazounis E, Allanazarova G, Stringer B. Wharton-Smith A, et al. Among authors: nyang wa bt. Trials. 2021 Dec 4;22(1):881. doi: 10.1186/s13063-021-05850-0. Trials. 2021. PMID: 34863253 Free PMC article. Clinical Trial.
21 results